|
The prognostic value of blood neutrophil-to-lymphocyte ratio (NLR) factor in advanced gastrointestinal stromal tumors (GIST) treated with sunitinib after imatinib failure. |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Blueprint Medicines; MSD; Novartis |
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Pfizer |
Research Funding - BMS Brazil (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Orphan Europe |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; Roche |
Speakers' Bureau - InfectoPharm |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Roche |
|
|
No Relationships to Disclose |